Filing Details

Accession Number:
0001437749-23-033803
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-06 19:54:50
Reporting Period:
2023-12-04
Accepted Time:
2023-12-06 19:54:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1625101 Pulse Biosciences Inc. PLSE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055919 W Robert Duggan 3957 Point Eden Way
Hayward CA 94545
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-04 20,000 $10.66 36,571,461 No 4 M Direct
Common Stock Acquisiton 2023-12-04 20,347 $10.66 36,591,808 No 4 M Direct
Common Stock Acquisiton 2023-12-04 27,000 $10.38 285,544 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2023-12-04 20,000 $0.00 20,000 $10.66
Common Stock Stock Option (right to buy) Disposition 2023-12-04 20,347 $0.00 20,347 $10.66
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2030-05-18 No 4 M Direct
0 2030-05-18 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 492,069 Indirect See footnote
Footnotes
  1. Volume-weighted average price.
  2. Shares are held by Blazon Corporation, of which the Reporting Person is the majority shareholder.
  3. Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder.
  4. Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a monthly basis following the Company's 2020 Annual Stockholder Meeting.
  5. Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a quarterly basis following the Company's 2020 Annual Stockholder Meeting.